Cargando…

Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes

The introduction of COVID-19 vaccination passes (VPs) by many countries coincided with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions f...

Descripción completa

Detalles Bibliográficos
Autores principales: Krueger, Tyll, Gogolewski, Krzysztof, Bodych, Marcin, Gambin, Anna, Giordano, Giulia, Cuschieri, Sarah, Czypionka, Thomas, Perc, Matjaz, Petelos, Elena, Rosińska, Magdalena, Szczurek, Ewa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053266/
https://www.ncbi.nlm.nih.gov/pubmed/35603303
http://dx.doi.org/10.1038/s43856-022-00084-w
_version_ 1784696961277886464
author Krueger, Tyll
Gogolewski, Krzysztof
Bodych, Marcin
Gambin, Anna
Giordano, Giulia
Cuschieri, Sarah
Czypionka, Thomas
Perc, Matjaz
Petelos, Elena
Rosińska, Magdalena
Szczurek, Ewa
author_facet Krueger, Tyll
Gogolewski, Krzysztof
Bodych, Marcin
Gambin, Anna
Giordano, Giulia
Cuschieri, Sarah
Czypionka, Thomas
Perc, Matjaz
Petelos, Elena
Rosińska, Magdalena
Szczurek, Ewa
author_sort Krueger, Tyll
collection PubMed
description The introduction of COVID-19 vaccination passes (VPs) by many countries coincided with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant. Some predicted epidemic scenarios for realistic parameter values yield new COVID-19 infection waves within two years, and high daily case numbers in the endemic state, even without introducing VPs and granting more freedom to their holders. Still, suitable adaptive policies can avoid unfavorable outcomes. While VP holders could initially be allowed more freedom, the lack of full vaccine effectiveness and increased transmissibility will require accelerated (re-)vaccination, wide-spread immunity surveillance, and/or minimal long-term common restrictions.
format Online
Article
Text
id pubmed-9053266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90532662022-05-20 Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes Krueger, Tyll Gogolewski, Krzysztof Bodych, Marcin Gambin, Anna Giordano, Giulia Cuschieri, Sarah Czypionka, Thomas Perc, Matjaz Petelos, Elena Rosińska, Magdalena Szczurek, Ewa Commun Med (Lond) Article The introduction of COVID-19 vaccination passes (VPs) by many countries coincided with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant. Some predicted epidemic scenarios for realistic parameter values yield new COVID-19 infection waves within two years, and high daily case numbers in the endemic state, even without introducing VPs and granting more freedom to their holders. Still, suitable adaptive policies can avoid unfavorable outcomes. While VP holders could initially be allowed more freedom, the lack of full vaccine effectiveness and increased transmissibility will require accelerated (re-)vaccination, wide-spread immunity surveillance, and/or minimal long-term common restrictions. Nature Publishing Group UK 2022-03-03 /pmc/articles/PMC9053266/ /pubmed/35603303 http://dx.doi.org/10.1038/s43856-022-00084-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Krueger, Tyll
Gogolewski, Krzysztof
Bodych, Marcin
Gambin, Anna
Giordano, Giulia
Cuschieri, Sarah
Czypionka, Thomas
Perc, Matjaz
Petelos, Elena
Rosińska, Magdalena
Szczurek, Ewa
Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
title Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
title_full Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
title_fullStr Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
title_full_unstemmed Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
title_short Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
title_sort risk assessment of covid-19 epidemic resurgence in relation to sars-cov-2 variants and vaccination passes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053266/
https://www.ncbi.nlm.nih.gov/pubmed/35603303
http://dx.doi.org/10.1038/s43856-022-00084-w
work_keys_str_mv AT kruegertyll riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT gogolewskikrzysztof riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT bodychmarcin riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT gambinanna riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT giordanogiulia riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT cuschierisarah riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT czypionkathomas riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT percmatjaz riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT peteloselena riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT rosinskamagdalena riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses
AT szczurekewa riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses